Clone:
REAL1161
Type of antibody:
Releasable fluorochromes, Primary antibodies, Recombinant antibodies
Applications:
MICS, IHC, IF
Alternative names:
LYVE1, CRSBP-1, CRSBP1, HAR, XLKD1

Specifications for LYVE-1 Antibody, anti-human, REAdye_lease™

Overview

Clone REAL1161 is an antibody fragment derived from the full LYVE-1 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity.
Clone REAL1161 recognizes the human LYVE-1 protein, also known as lymphatic vessel endothelial hyaluronic acid receptor 1, LYVE1, XLKD1 or CRSBP-1. LYVE-1 is a type I integral membrane glycoprotein, which is a lymph-specific receptor for hyaluronan and homologous to CD44. LYVE-1 is mainly expressed in endothelial cells lining lymphatic vessels, but also in normal hepatic blood sinusoidal endothelial cells. LYVE-1 is an indicator for human hepatocellular carcinoma. It is involved in lymphatic hyaluronan transport, in tumor metastasis and autocrine regulation of cell growth. Lyve-1 is expressed in liver cancer.
For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675).

Alternative names

LYVE1, CRSBP-1, CRSBP1, HAR, XLKD1

Detailed product information

Technical specifications

CloneREAL1161
Clonalitymonoclonal
Isotype controlControl Antibody
Hostcell line
Type of antibodyReleasable fluorochromes, Primary antibodies, Recombinant antibodies
Specieshuman
AntigenLYVE-1
Alternative names of antigenLYVE1, CRSBP-1, CRSBP1, HAR, XLKD1
Distribution of antigenepithelial cells, tumor

References for LYVE-1 Antibody, anti-human, REAdye_lease™

Publications

  1. Banerji, S. et al. (1999) LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. 144(4): 789-801
  2. Mouta Carreira, C. et al. (2001) LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. 61(22): 8079-8074
  3. Rinaldi, E. et al. (2018) LYVE-1 is 'on stage' now: an emerging player in dendritic cell docking to lymphatic endothelial cellsElena Rinaldi and Fulvio Baggicorresponding author. Cell. Mol. Immunol. 15(7): 663-665